Publish innovative Results and secure Attention.

 

Here you will find a selection of articles that have been published in international peer-reviewed journals by the company founder as the initiator.

International Approval with one Idea.

For products that have already received market approval, we conduct clinical studies in which the medical benefits and safety of the products are demonstrated. We publish the study results with you in high-ranking international journals and support you in ensuring that your product is reimbursed by the health insurance funds (see also medical aids register). Our customers use the study results to market their medical devices efficiently.

Recently, in an international retrospective clinical evaluation, we demonstrated the benefits and safety of a medical device for dynamic standing. The publication has been very well received by the research community and is being used efficiently by our customers to market the medical device. We also successfully published the results of a prospective study of a novel non-invasive medical device that caused patients with an elevated cardiovascular risk profile to lose weight over a long period of time (more than 2 years).

  • Schmidt-Lucke C, Käferle J, Rydh Berner BM, Ahlborg L, Hansen HM, Skjellvik Tollefsen U, Thon T, Damkjær Moen R, Pekanovic A, Tornberg ÅB, Lauruschkus K. Effect of assisted walking-movement in patients with genetic and acquired neuromuscular disorders with the motorised Innowalk device: an international case study meta-analysis. PeerJ. 2019
  • von Seck P, Sander FM, Lanzendorf L, von Seck S, Schmidt-Lucke A, Zielonka M, Schmidt-Lucke C. Persistent Weight Loss with a Non-invasive Novel Medical Device to Change eating behaviour In Obese Individuals With High-risk Cardiovascular Risk Profile. PLoS ONE. 2017

Bedside to Bench and back forward.

Medical translational research takes up problems related to our patients into the lab. Here, a multi-disciplinary team in basic science helps to make results useful for practical applications to enhance our understanding of disease, develop new diagnostics, and translate our findings into new therapeutic options. Curiosity, precision, well-founded and sound scientific knowledge with a good feeling for relevant problems characterise academic research with clinical applicability. It is now well-known that circulating angiogenic cells play an indispensible role in vascular regeneration and organ preservation. Our work has been reproduced and cited manifold.

  • Schmidt-Lucke C, Rossig L, Fichtlscherer S, Vasa M, Britten M, Kamper U, Dimmeler S, Zeiher AM. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation. 2005
  • Fichtlscherer S, Schmidt-Lucke C, Bojunga S, Rossig L, Heeschen C, Dimmeler S, Zeiher AM. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for ‘pleiotropic’ functions of statin therapy. Eur Heart J. 2006
  • Schmidt-Lucke C, S Fichtlscherer, A Aicher, C Tschöpe, H-P Schultheiss, A M Zeiher, S Dimmeler. Quantification of circulating endothelial progenitor cells using the modified ISHAGE protocol. PLoS ONE. 2010
  • Schmidt-Lucke C, Stephan Fichtlscherer, Lothar Rössig, Ulrike Kämper, Stefanie Dimmeler. Improvement of endothelial damage and regeneration indexes in patients with coronary artery disease after 4 weeks of statin therapy. Atherosclerosis. 2010
  • GP Fadini, Maruyama S, Ozaki T, Taguchi A, Meigs J, Dimmeler S, Zeiher A, de Kreutzenberg S, Avogaro A, Nickenig G, Schmidt-Lucke C, Werner N. Circulating progenitor cell count for cardiovascular risk stratification. A pooled analysis. PLoS ONE. 2010

Tread new Paths. Think unusual. Free of Conventions.

Pattern of clinical disease caused by human parvovirus B19 (B19V) is generally a self-limiting subclinical disorder. However, in certain individuals B19V is a fatal disease. B19 V is the most common viral pathogen associated with inflammatory cardiomyopathy. Interestingly, B19V infection is restricted to cardiac endothelial cells, but not cardiomyocytes in this disease. B19V infection of endothelial cells results in apoptosis, the programmed cell death. Patients with B19V cardiomyopathy present endothelial dysfunction and show elevated numbers of circulating apoptotic endothelial cells. How can B19V persist in the heart over long time periods? What are the mechanisms of damage in B19V-infected bone marrow-derived cells? These findings are being published shortly in a high-ranking journal. 

  • Schmidt-Lucke C, Zobel T, Escher F, Tschöpe C, Lassner D, Kühl U, Gubbe K, Volk HD, Schultheiss HP. Human Parvovirus B19 (B19V) Up-regulates CXCR4 Surface Expression of Circulating Angiogenic Cells: Implications for Cardiac Ischemia in B19V Cardiomyopathy. J Infect Dis. 2018
  • Schmidt-Lucke C, Spillmann F, Bock T, Kühl U, Van Linthout S, Schultheiss HP, Tschöpe C. Interferon-beta modulates endothelial damage in patients with cardiac persistence of parvovirus B19. J Infect Dis. 2010
  • Pozzuto T, von Kietzell K, Bock T, Schmidt-Lucke C, Poller W, Zobel T, Lassner D, Zeichhardt H, Weger S, Fechner H. Transactivation of human parvovirus B19 gene expression in endothelial cells by adenoviral helper functions. Virology. 2011
  • Schmidt-Lucke C, Escher F, Van Linthout S, Kühl U, Miteva K, Ringe J, Zobel T, Schultheiss HP, Tschöpe C. Cardiac migration of endogenous mesenchymal stromal cells in patients with inflammatory cardiomyopathy. Mediators Inflamm. 2015
  • Schmidt-Lucke C, Zobel T, Schrepfer S, Kühl U, Wang D, Klingel K, Becher PM, Fechner H, Pozzuto T, Van Linthout S, Lassner D, Spillmann F, Escher F, Holinski S, Volk HD, Schultheiss HP, Tschöpe C. Impaired endothelial regeneration through human parvovirus B19-infected circulating angiogenic cells in cardiomyopathy. J Infect Dis. 2015
  • Zobel T, Bock CT, Kühl U, Rohde M, Lassner D, Schultheiss HP, Schmidt-Lucke C. Telbivudine Reduces Parvovirus B19-Induced Apoptosis in Circulating Angiogenic Cells. Viruses. 2019

Change Guidelines.

The ACE-Study was widely acclaimed and received great international interest. This investigator-initiated study broadened the indication of Enoxaparin. In this randomised, prospective multicentre-study, Enoxaparin showed non-inferior to unfractionated heparin and phenprocoumon in TEE-guided cardioversion of persistent non-valvular atrial fibrillation.

  • Schmidt-Lucke C, Paar WD, Stellbrink C, Nixdorff U, Hofmann T, Meurer J, Grewe R, Daniel WG, Hanrath P, Mugge A, Klein HU, Schmidt-Lucke JA. Quality of anticoagulation with unfractionated heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for non-valvular atrial fibrillation. Sub-analysis from the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Thromb Res. 2007
  • Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mugge A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke JA. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation. 2004
  • Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mugge A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke JA. Use of subcutaneous enoxaparin compared to intravenous heparin and oral phenprocoumon in the setting of cardioversion – the ACE study (Anticoagulation in Cardioversion using Enoxaparin). Card Electrophysiol Rev. 2003
  • Schadlich PK, Schmidt-Lucke C, Huppertz E, Lehmacher W, Nixdorff U, Stellbrink C, Brecht JG. Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation: a statutory health insurance perspective from Germany. Am J Cardiovasc Drugs. 2007

Sound Knowledge in Theory and Practice.

Recognition among Experts.

Harrison's Principles of Internal Medicine in its 18th edition is widely regarded as one of the most authoritative American books on internal medicine and has been described as the "most recognised book in of medicine". This encyclopaedia has been translated and adapted for the German-speaking countries by around 300 specialists. Two innovative chapters have been entrusted to the founder’s care in two consecutive editions. 

  • Schmidt-Lucke C. Regenerative Medizin, Stammzellbiologie und Anwendungen der Stammzellbiologie in der klinischen Medizin, in Harrison 18. Auflage; ABW, 2016
  • Schmidt-Lucke C. Regenerative Medizin, Stammzellbiologie und Anwendungen der Stammzellbiologie in der klinischen Medizin, in Harrison 18. Auflage; ABW, 2012
  • Schmidt-Lucke C. Regenerative Medizin, Stammzellbiologie und Anwendungen der Stammzellbiologie in der klinischen Medizin, in Harrison 17. Auflage; ABW, 2009

 

Digitalisation of the health market most likely is a similar revolution as antibiotics have been in the past. Medical apps increasingly influence our behaviour. Despite huge amounts of medical apps on the market, only a small minority has proven evidence or complies with German or European regulations as medical device. We provide assistance and services for developers and companies to tackle the challenges for this disruptive technology.

  • Schmidt-Lucke C. Medizinische Apps zwischen Lifestyle und Medizinprodukt. Going public, 2016.
  • Schmidt-Lucke C. Gründen mit einer medizinischen App. Starting up, 2017.

 

With over 1000 questions of pharmacology of internal medicine and cardiology, medical students specifically prepare themselves for oral examinations and effectively keep the knowledge for their patients. – in German

  • Aicher A, Adler K, Schmidt-Lucke C und Brenner W. Pharmakologie in Frage und Antwort. Urban & Fischer Verlag, München – Jena, 2005

 

Principles and Practice of Panvascular Medicine is a comprehensive textbook by the editors Peter Lanzer and Eric J. Topol. It covers cardiology, cardiac surgery, vascular surgery, radiology, neurology, neurosurgery, and vascular medicine (angiology), thus providing an interdisciplinary and integrated perspective of modern vascular medicine. It is aimed at junior practitioners and experts. The founder was entrusted to contribute to fundamental areas arterial disease.

  • Schmidt-Lucke C. Peripheral Artery Physiology and Pathophysiology: Special Considerations, in: Principles and Practice of Panvascular Medicine (eds. Lanzer P, Topol E), Springer-Verlag, Heidelberg-New York, 2002
  • Schmidt-Lucke C. Mikroperfusionsstörungen bei peripherer arterieller Verschlußkrankheit. Med Welt 53: 206 –10, 2002

 

© 2019 MEDIACC GmbH